Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sheesh, Friday's selling volume was disappointing. I was expecting a buyers day where the PPS went up.
I wonder how long we have to wait until we see the CBIS surprise the good Dr. was talking about.
outstanding shares
All I can say is .... Whoa, that's huge !!
I really hope Californians and others legalize the weed, but I have to agree that the business model for CBIS does not depend upon legalization. That would be like legalizing opium and then there would go some of the profits of pharmas.
The current dispensary model will be around for years and that should bring in plenty of revenues in various states around the country.
Anyway, I know the lower PPS will bring higher volume, a better analysis is the daily $$$$ being traded.
Yeah, that was my .10 bid on L2. Got it filled today, Yahoo!!
Though, the buy/sell counts differed from Scottrade than with IHUB. A bunch of the buys must have been sell orders in disguise, because the price seemed to go down after all the buy pressure.
The difference between the ask and bid was rather huge today, and it looks like it may be larger tomorrow judging on the AH bid/ask .102/.144.
Would be great to see this end on friday above .13 or .14 !!!
Today is the day .... the company expected to retire most of its debt by today !!!! As a result, the selling pressure should ease and the buying pressure will raise $$$$$ in PPS !!!
How about the .13 cent sell-off this morning to bring the SP down.
MM's are bringing it lower, hopefully that's a good sign that there might be some action soon.
And... GWP hit a 52 week high of $156 last week on the news.
MM's trying hard to bring this down.
LOL, too much buying pressure this morning for them handle that.
Strong am volume. GLTA
Yeah baby, but that's in Washington, not Oregon. Anyway, there is an increase in MMJ proposals all across the USA. Go NY!!!
I agree that the chart shows a steep slope, but I would not compare MJ stock with CBIS. The ski slope that MJ shows may be the result of lack of a business focus, which seems to change with the seasons....I expect more snow on that slope.
On the other hand, the focus of CBIS has been consistently focused on development of medicine that can affect millions. The recent news about GW Pharm, dispensary acquisitions to fund current operations and generate revenue, leads more to investor confidence that a "product" may be approved that will light this candle.
The rest of this week will be an indicator, imo, of whether we will flounder more, or head north. I do think the pressure is building here at CBIS judging by the increase in volume.
The chart looks really good today with the volume we've had
check out chart here and see the green
Hope this trend continues because CBIS is getting national exposure with the additional PR about the Montana Gov.
Oregon's legization bill is dead, a dispensary initiative however will be up for a vote come Nov. (and this would supplement an exiting marijuana program)
At least no one is selling.
I see that CBIS used a stock promoter earlier this month. I wrote to Mike F. and told him that was not a good idea....they used nebulastocks.com for a price of 5000. Nebulastocks claims on the web site that CBIS had %2300 climb as a result. That's fraud in my book.
Please call M.F and ask him not to use the pumpers, because, imo, in the long run they hurt the PPS.
GW Pharma sells pot spray.
Here's the story and link
By JASON DOUGLAS
LONDON—A drug manufactured from cannabis went on sale in the U.K. Monday as a treatment for symptoms of multiple sclerosis.
Sativex, which is made from cannabis plants grown at secret locations in England by developer GW Pharmaceuticals PLC, is the first prescription drug made from cannabis to officially go on sale anywhere in the world. It offers legal access to the beneficial effects of an illegal drug that thousands of multiple-sclerosis sufferers have smoked in an attempt to relieve their pain.
It is also a boon for small U.K. drug developers, which have struggled in recent years to win investor confidence—and funding—because of setbacks in clinical trials of their experimental medicines.
Sativex was approved Friday by the U.K. Medicines and Healthcare products Regulatory Agency, or MHRA, as a treatment for spasticity in multiple- sclerosis patients who aren't benefiting from other treatments. It had been in development for 11 years.
Sativex's approval follows successful clinical trials. The drug will be marketed in the U.K. by Germany's Bayer AG , which said Monday it will cost the country's state-run National Health Service roughly £11, or about $16, a day for each patient.
Sativex has been available previously on a limited basis to patients in Canada and the U.K. but hadn't yet been marketed.
The formal launch of Sativex represents a milestone in treating the disease, said Pam Macfarlane, chief executive of the MS Trust, a charity that has campaigned for a licensed medicine derived from cannabis to be made available to multiple-sclerosis sufferers.
The charity has long known cannabis helped patients' symptoms, Ms. Macfarlane said.
Roughly one-third of multiple-sclerosis patients are believed to have tried cannabis to get relief, with some surveys suggesting the proportion is as high as 43%, said GW Pharmaceuticals Managing Director Justin Gover.
Bayer said there are about 100,000 people in the U.K. who suffer from multiple sclerosis, and many experience spasms, cramps and similar symptoms known collectively as spasticity.
However, Sativex doesn't work for everyone. Bayer estimates about 11,500 people in the U.K. will be eligible for treatment with Sativex but only about half of them will get a good response.
Spain is expected to be the next country to approve Sativex for sale. Almirall SA holds the drug's marketing license in Spain and is GW's partner for the rest of Europe, excluding the U.K.
Mr. Gover said Almirall and GW will be seeking approval in Germany, Italy, France and other European countries later this year.
Analysts at brokers Nomura Code Securities and KBC Peel Hunt estimate that sales of Sativex as a multiple-sclerosis spasticity treatment will peak in Europe at about £50 million a year. Piper Jaffray forecasts peak annual sales of at least £100 million.
A bigger potential prize exists in the U.S., where Sativex is being developed as a painkiller for cancer patients. Mr. Gover said GW and U.S. partner Otsuka Pharmaceutical Co. of Japan are scheduled to meet with the Food and Drug Administration this summer to discuss Phase III trials.
Write to Jason Douglas at jason.douglas@dowjones.com
I does seem obvious there were too many short sales today.
I also wonder why there weren't more buy-in today. Am puzzled as well, had hopes for reaching the 20's today.
Yes, I think that is what I want, please sell your shares.
Yeah good, regulate them out of existence. You won't see any PR's telling you how many dispensary clients CMSI lost because of the shut downs.
Al Capone would have been proud of this law. Less competition should keep the price up and payments flowing, albeit less sales.
That's nuts. You would think they would cover when the PPS was low and make $$$$. Seemed like they kept the price low today with all the shorts.
If there is any type of good volume Friday and if the shorts have to cover, price should be excellent, at least between .17 and .22.
I am hoping that more entries into this market due to PR and price valuation. We need to get back to the 20 range.
HB 1284 is not good news for dispensaries or patients because it places more restrictions upon them. However, Colorado activists are looking to form a committee to legalize cannabis in 2012.
There was good news in Oregon yesterday. The Court of Appeals upheld medical marijuana patients rights to keep their concealed weapons permit. And the Oregon dispensary initiative I-28 have turned in enough signatures to qualify for Novembers ballot.
Best of all, the Oregon Board of Pharmacy reclassified marijuana from schedule I to schedule II, at least they gave recognition that marijuana has medical uses !
Here is today's pain medicine from the new dispensary.
Montana Pain Management
Huge buy orders this morning and they are slapping the ask. Looks like a little resistance at .12 and .13 and then it should slap the asks a little faster.
At this rate we may come close to 1m shares traded today!
Yahoo!!
Feel sorry for those whose sold on the Kubby scare.
Still more good news from Oregon today. Indeed, with two other pieces of news that I previously posted today, Oregon Board of Pharmacy reclassified marijuana from a schedule I drug to a schedule II drug, thereby recognizing its medical use.
Oregon joins four other states -- Alaska, Iowa, Montana, Tennessee along with the District of Columbia that have classified marijuana as a therapeutic substance.
June_2010_PressReleaseMarijuana.doc
This is a trend that continues to show the medical value of weed.
Good day for cannabis lovers in Oregon today.
First, the Oregon Court of Appeals decided today that patients under the medical marijuana program can keep their concealed gun permits.
Secondly, initiative petition to add dispensaries on to our existing medical marijuana program appears to have enough signatures to qualify for the ballot.
More reason to hoot and holler in November !!
Kubby still hold his patents, processes, and knowledge.
However, you cannot patent a delivery method such as a lozenge, cannot patent a plant, so CBIS can make whatever products that they produce with their own knowledge, and their own cannabis.
Much has happened since Kubby left CBIS. Like candy bars, nobody can patent chocolate, but they can patent the way they process them to make them unique. How hard can it be to come up with a new candy bar ?? Okay, 33% cocoa rather than 30%, and add caramel in the middle??
JD posted
My guess is that there will news on Monday.
I know that some of you may be all in... but this is a good time to add. A few months ago an analyst gave a target of .42 and it won't take too long until the company will be out of debt and producing a profit report.
Don't forget that Dr. Abrams is on board.
Harmful? Helpful?
Medical marijuana inspires strong opinions, but what does science say? A look at the pros, cons.
August 18, 2008|Jill U. Adams, Special to The Times
Depending ON whom you ask, marijuana is a dangerous drug that should be kept illegal alongside heroin and PCP, or it's a miracle herb with a trove of medical benefits that the government is seeking to deny the public -- or something in between: a plant with medical uses and drawbacks, worth exploring.
As the political debates over medical marijuana drag on, a small cadre of researchers continues to test inhaled marijuana for the treatment of pain, nausea and muscle spasms.
All drugs have risks, they point out -- including ones in most Americans' medicine cabinets, such as aspirin and other pain-relievers or antihistamines such as Benadryl. Doctors try to balance those risks against the potential for medical good -- why not for marijuana as well, they ask.
The truth, these researchers say, is that marijuana has medical benefits -- for chronic-pain syndromes, cancer pain, multiple sclerosis, AIDS wasting syndrome and the nausea that accompanies chemotherapy -- and attempts to understand and harness these are being hampered. Also, they add, science reveals that the risks of marijuana use, which have been thoroughly researched, are real but generally small.
Dr. Donald Abrams, chief of hematology and oncology at San Francisco General Hospital and professor of clinical medicine at UC San Francisco, says he sees cancer patients in pain, not eating or sleeping well, experiencing nausea and vomiting from treatment, and being depressed about their situation. He says he is glad that he lives in California, where use of medical marijuana is allowed by state law, although federal officials continue to raid cannabis dispensaries in the state and scrutinize practices of physicians who specialize in writing cannabis recommendations for patients.
"I can talk to patients about medicinal cannabis [and] I'm often recommending it to them for these indications," Abrams says.
Old News but....
Scientists, FDA at odds over benefits of marijuana
May 02, 2009
BRIAN NEWSOME
THE GAZETTE
Biology professor Robert Melamede is almost manic as he preaches the virtues of medical marijuana. He spews scientific jargon as he discusses the "thousands" of studies that prove it's one of the greatest drugs in modern medicine.
"In my mind, it's the first thing you should use, not the last," he says. "We've had it backwards."
On the other side is the U.S. Food and Drug Administration, which declared in 2006 that "no sound scientific studies supported medical use of marijuana treatment in the United States."
In those two extremes lies the problem. At a time when more than a dozen states have legalized marijuana for medicinal use and at least two others are considering it, just how useful marijuana is as medicine remains largely a mystery. Major clinical research into the drug has been stymied by politics and controversy. And the known facts about marijuana are often laced with spin and emotion from the two sides that Melamede and the FDA represent.
Physicians and scientists familiar with marijuana's medicinal uses generally agree that the drug has at least some benefits for some patients. In 1999, the Institute of Medicine, home to some of the world's top scientists, acknowledged the drug's potential and called for more research into it. The American Medical Association has taken a similar position.
But measured responses to marijuana are often lost amid the emotions of advocacy or condemnation.
Cannabis cheered
Melamede, who teaches at the University of Colorado at Colorado Springs, can quote studies on marijuana like a preacher quotes the Bible. He is both a scholar and a patient on the state's registry, and he says the drug has the potential to benefit almost everyone: stroke patients, cancer patients, the mentally ill and possibly even soldiers exposed to chemical warfare.
"For people with strokes, the first thing they should be doing is toking up a joint," says Melamede, who uses marijuana to treat chronic back pain. And he notes one claim in which marijuana reversed some of the effects of Sarin, a deadly nerve gas, in mice. His latest hypothesis: Eating cannabis could help fight avian and swine flu.
He and other supporters point to patients who have benefited from medical marijuana - including Frank Blakely, who at 60 suffers from cerebral palsy. He also has a degenerative nervous disorder, one working kidney and a pacemaker to correct a slow heartbeat, and he lost his right leg below the knee to antibiotic-resistant bacteria.
"The doctors have given me absolutely no hope of things doing anything but getting worse," says Blakely, a retired software developer. Marijuana, he says, has helped him reduce his reliance on morphine and oxycodone.
"It doesn't completely replace the oxycodone or the morphine, but for me it replaces about 75 percent ... The part of me that is in pain, it helps divorce me from those parts, whereas the narcotics overwhelm the pain but they overwhelm me in the process. With the number of medicines I take, everything is contraindicated, and it's good to have a medicine without side effects."
Searching for science
But animal studies, anecdotes and the bulk of existing research don't measure up to the standards of clinical trials, which drive drug approvals and treatments. For pharmaceuticals, mice may be the beginning, but the end is usually a set of extensive human trials with rigorous controls and procedures to ensure other factors don't taint results. In many instances, what proves true for lab rats doesn't pan out for humans.
"There's research. But it's crappy research," says Dr. Randall J. Bjork, a Colorado Springs neurologist who is one of more than 600 Colorado doctors who will certify patients to use medical marijuana. "It would be nice to see something definitive printed up in the New England Journal of Medicine or Annals of Neurology."
He said his marijuana-using patients do seem more able to manage their conditions than do many other patients. He sees them just once a year, when it's time to re-certify them for the registry. And he's intrigued by reports from other doctors, such as a Prague physician who claimed two-thirds of his Parkinson's disease patients have improved on marijuana.
Yet Bjork remains skeptical of the effectiveness of a drug that has yet to be tested in large-scale, well-organized studies. For now, he considers marijuana a low-tier treatment and has never suggested marijuana to a patient who wasn't already inquiring about it.
Pot and pain
Dr. Igor Grant would disagree that all research into medicinal marijuana is shoddy. He runs the University of California at San Diego's Center for Medicinal Cannabis Research, established after California became the first state to legalize marijuana for medicinal use in 1996.
Four controlled human studies at Grant's center, led by different researchers at different campuses, found marijuana was effective in treating certain types of pain. Three of them explored the use of marijuana to relieve neuropathy, a type of pain associated with a number of conditions, in AIDS patients. The fourth evaluated pain relief for healthy volunteers who agreed to have pain induced under the skin.
"I would say that, in general, the size of the statistical effect was about what we see with the other treatments," he says. He sees the potential for marijuana to be developed into a whole class of medications.
Even so, he acknowledges that clinical research is in its infancy.
A Catch-22
The kind of gold-standard research that Bjork and Grant seek isn't likely to come soon.
Researchers face regulatory hurdles in obtaining or growing pot, not to mention a lack of funding.
When asked why more people are not doing research like his, Grant jokes: "I'd like you to do a study on a completely useless and dangerous drug."
Bjork suspects some scholars might be afraid to wade into the controversy.
Melamede is convinced clinical trials would only confirm what early studies have shown, and he's started a company to raise money to support such research.
"The real tragedy is that nobody does the real science on it," he says.
It's nice to close that chapter with Cannex/Kubby and get it behind us.
Time to move forward without the monkey on the back.
gimmesum wrote:
Now that was one funny post.
The company practically stated that price was not going up.
They did say they had a plan, but everyone keeps asking ... are we there yet, are we there yet.
This plan requires patience. GLTA.
Wow Louie !! you really do your DD well.
Louie wrote: "because i know he is on this broad..(biggest pumper..."
Butt..... do you really think he will tell us which broad he is pumping ?? Publicly ??
Yeah, lol, you'll be able to pick more up on Friday when the flippers sell the divi's. Chart shows support before the div at .015.
You are right, pps did not finish at .045 today, though it did come close. MM's backed off of .05 with all the sells. More selling pressure could bring it down to a secondary support of .042 on Friday. Need more buyers to bring it up... and it will eventually.
Low volume, declining pps, looks like .045 at eod
I agree. Lots of buys this morning. Hoping to hit .07 or .08 by EOD
Tuesday is buy-in day. Should go up to 1.20 IMO.
This should be fun to watch...maybe a gap up to .65 at the bell? And a race upward from there !!! Lots of volume too.